Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
(US Sites) Daiichi Sankyo Contact for Clinical Trial Information
CONTACT
(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information
CONTACT
Lead
Daiichi Sankyo
DS-3939a is an antibody drug conjugate (ADC) being developed for the treatment of malignant tumors. This is a first-in-human, dose-escalating clinical study divided into 2 parts: the Dose Escalation Part (Part 1) and the Dose Expansion Part (Part 2).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted